The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	17.52B +5.1%
Revenue (ttm)	40.05B +15.3%
Net Income	2.67B +10.9%
EPS	12.60 +10.9%
Shares Out	211.60M
PE Ratio	6.57
Forward PE	n/a
Dividend	3.50 (4.23%)
Ex-Dividend Date	Nov 19, 2025

Volume	326,638
Open	83.00
Previous Close	82.80
Day's Range	82.00 - 83.30
52-Week Range	68.60 - 88.70
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 15, 2026

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacturing, marketing, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and ...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,025
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In fiscal year 2025, The ACME Laboratories's revenue was 35.94 billion, an increase of 12.54% compared to the previous year's 31.93 billion. Earnings were 2.43 billion, a decrease of -1.12%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 26, 2026

Data Sources Report a data error